8 research outputs found
Non neoplasic process of type don't touch
UNIFESP DDISanta Casa de Misericórdia de São PauloUNIFESP-EPMUNIFESP, DDIUNIFESP, EPMSciEL
Imaging evaluation of the knee cystic formations
Diagnósticos da AméricaClÃnica Miranda e WiermannHospital Santa Casa de Misericórdia de São Paulo Serviço de Diagnóstico por Imagem Setor MusculoesqueléticoUniversidade Federal de São Paulo (UNIFESP)UNIFESP Departamento de DiagnósticoUNIFESP, Depto. de DiagnósticoSciEL
Estudo por imagem da articulação carpometacarpal do polegar Imaging study of the carpometacarpal joint of the thumb
Santa Casa de Misericórdia de São Paulo Serviço de Diagnóstico por ImagemUniversidade Federal de São Paulo (UNIFESP) Departamento de Diagnóstico por ImagemSanta Casa de Misericórdia de São Paulo Departamento de Ortopedia e TraumatologiaUNIFESPUNIFESP, Depto. de Diagnóstico por ImagemUNIFESPSciEL
RaÃzes meniscais: anatomia e avaliação por meio da ressonância magnética Meniscal roots: anatomy and evaluation by magnetic resonance imaging
Empagliflozin in Patients with Chronic Kidney Disease
Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo